Pharmafile Logo

LY-CoV555

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

The company is also evaluating the use of the vaccine in children aged from six months

- PMLiVE

WHO joins calls for equitable access to healthcare products ahead of future pandemics

The WHO, WIPO and WTO gathered at the Joint Technical Symposium on 16 December

- PMLiVE

Eli Lilly and EVA Pharma collaborate to enhance insulin access in Africa

The African-made insulin products are expected to reach one million people per year by 2030

- PMLiVE

Eli Lilly shares adjusted financial guidance for 2023

Lilly’s projection for revenue in the new year is set to be between $30.3bn and $30.8bn

- PMLiVE

WHO member states commit to producing a pandemic accord in 2023

The ‘zero draft’ will be a legally binding agreement, part of the WHO Constitution

- PMLiVE

UK Government launches new taskforce to help NHS tackle COVID-19 backlogs

Experts will focus on how the NHS can utilise existing capacity in the independent sector

- PMLiVE

FDA approves updated COVID-19 boosters for children aged from six months

The Moderna and Pfizer/BioNTech boosters both target the BA.4/BA.5 omicron subvariants

- PMLiVE

EMA’s emergency task force backs bivalent COVID-19 vaccines for primary vaccination

National authorities may decide to use the vaccines in their primary vaccination campaigns

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

- PMLiVE

Lilly shares positive Verzenio data as adjuvant early breast cancer therapy

Results were shared in The Lancet Oncology and at the San Antonio Breast Cancer Symposium

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links